Co-Diagnostics announced key regulatory approvals and expanded its commercial reach in South Asia, including India and neighboring countries, enhancing its market potential to $13 billion. The company progressed clinical studies for upper respiratory and tuberculosis tests, preparing for FDA submissions and performance trials. Despite revenue growth to $0.15 million, Co-Diagnostics reported a net loss of $9.1 million in Q1 2026, driven by increased R&D and operational expenses as it invests in scaling its molecular diagnostics platform globally. The company also expanded its intellectual property portfolio and manufacturing capabilities in the Middle East, signaling strategic moves toward commercialization and international market penetration.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Brazil Potash Corp. disclosed a procedural filing by the Brazilian Federal Public Defender’s Office seeking to suspend activities at its Autazes potash project. The filing challenges prior favorable court decisions but does not introduce new facts or...
DT Midstream, Inc. will announce its financial results for the second quarter of 2026 before the market opens on July 30, 2026. The company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss the results. Investors and the publ...
UK GDP grew 0.8% over three months, beating expectations and showing resilience despite geopolitical risks. The FTSE 100 opened lower amid mixed company results, with major takeovers announced for Rotork (£4.1bn by ABB), Gooch & Housego (£345.6m by A...
Bitcoin briefly reached a three-week high near $65,600 before retreating to around $64,000, influenced by lower-than-expected US inflation data and geopolitical tensions. Ethereum also reversed from a six-week peak near $1,950, slipping below $1,900....
